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Abstract
Introduction The aims of this study were, first, to investigate the
in vivo effects of treatment with avocado/soybean
unsaponifiables on the development of osteoarthritic structural
changes in the anterior cruciate ligament dog model and,
second, to explore their mode of action.
Methods Osteoarthritis was induced by anterior cruciate
ligament transection of the right knee in crossbred dogs. There
were two treatment groups (n = 8 dogs/group), in which the
animals received either placebo or avocado/soybean
unsaponifiables (10 mg/kg per day), which were given orally for
the entire duration of the study (8 weeks). We conducted
macroscopic and histomorphological analyses of cartilage and
subchondral bone of the femoral condyles and/or tibial plateaus.
We also conducted immunohistochemical analyses in cartilage
for the following antigens: inducible nitric oxide synthase, matrix
metalloproteinase (MMP)-1, MMP-13, a disintegrin and
metalloproteinase domain with thrombospondin motifs
(ADAMTS)4 and ADAMTS5.
Results The size of macroscopic lesions on the tibial plateaus
was decreased (P = 0.04) in dogs treated with the avocado/
soybean unsaponifiables. Histologically, in these animals the
severity of cartilage lesions on both tibial plateaus and femoral
condyles, and the cellular infiltration in synovium were
significantly decreased (P = 0.0002 and P = 0.04, respectively).
Treatment with avocado/soybean unsaponifiables also reduced
loss of subchondral bone volume (P  < 0.05) and calcified
cartilage thickness (P  = 0.01) compared with placebo.
Immunohistochemical analysis of cartilage revealed that
avocado/soybean unsaponifiables significantly reduced the
level of inducible nitric oxide synthase (P < 0.05) and MMP-13
(P = 0.01) in cartilage.
Conclusions This study demonstrates that treatment with
avocado/soybean unsaponifiables can reduce the development
of early osteoarthritic cartilage and subchondral bone lesions in
the anterior cruciate ligament dog model of osteoarthritis. This
effect appears to be mediated through the inhibition of inducible
nitric oxide synthase and MMP-13, which are key mediators of
the structural changes that take place in osteoarthritis.
Introduction
Treatment of osteoarthritis (OA) is becoming a major medical
issue, with aging of the world's population. This disease is by
far the most common musculoskeletal disorder, and it is
responsible for a significant portion of the financial costs
related to treatment of arthritic conditions. With the predicted
increase in incidence of OA in coming decades, the costs
related to this disease are becoming a serious concern. More
people are surviving major medical problems such as cardio-
vascular and neoplastic diseases, and expectations of the
baby boomers include increased longevity as well as good
quality of life. Consequently, the challenge of improving the
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nitric oxide; OA: osteoarthritis; PBS: phosphate-buffered saline; TGF: transforming growth factor.Arthritis Research & Therapy    Vol 11 No 2    Boileau et al.
Page 2 of 9
(page number not for citation purposes)
effectiveness of OA treatments is of significant importance,
particularly if the treatment may also reduce or halt progres-
sion of the disease.
The pharmacological treatment of OA includes the use of
agents such as nonsteroidal anti-inflammatory drugs but also
others, such as avocado/soybean unsaponifiables Expan-
science™ (ASU; Laboratoires Expanscience, Courbevoie,
France) [1], which are composed solely of the total fraction of
unsaponifiables of avocado and soybean oils in proportions of
one-third to two-thirds, respectively. ASU are a member of
what are called 'slow-acting drugs for OA', which have been
demonstrated to be effective in relieving OA symptoms [2].
Preclinical studies have shown that, in vitro, ASU have an
inhibitory effect on IL-1β and stimulate collagen synthesis in
articular chondrocytes [3]. In another in vitro model, ASU pre-
vented – in part – the deleterious action of IL-1β on synovial
cells and on rabbit articular chondrocytes [4]. They can also
inhibit the stimulating action of IL-1β on stromelysin and colla-
genase and inhibit production of IL-6, IL-8 and prostaglandin
E2 [5]. In addition, it was demonstrated that ASU could exert
an anabolic effect by stimulating the expression of transform-
ing growth factor (TGF)-β1 and plasminogen activator inhibi-
tor-1 by articular chondrocytes [6]. Oral treatment with ASU in
normal dogs was also shown to increase TGF-β1 and TGF-β2
levels in knee synovial fluid [7]. In vivo, ASU were found to
reduce significantly the occurrence of lesions on cartilage in
the postcontusive model of OA in rabbits [8] and to improve
the subchondral bone structure in an ovine OA model induced
by meniscectomy [9].
In addition to the above findings, and most interesting are the
results from clinical trials that have shown a beneficial effect of
ASU on clinical symptoms of knee and hip OA, with a carry-
over effect that persists after termination of treatment [10-12].
The primary aim of the present study was to explore the effects
of treatment with ASU on the development of early structural
changes in an experimental OA dog model. The second objec-
tive was to identify the mechanisms by which the effects of
ASU are exerted in this model. In brief, this study was
designed to provide useful insight into the mode of action of
ASU on the OA pathological process.
Materials and methods
Experimental group
Sixteen adult crossbred dogs (aged 2 to 3 years), each weigh-
ing 20 to 25 kg, were used in this study. They were housed in
a large kennel in individual galvanized steel cages (1 m [width]
× 1.75 m [length] × 2.4 m [height]), each separated by a
panel. All cages were equipped with an automatic watering
system. Dogs were selected after complete physical and mus-
culoskeletal evaluations by a veterinarian. Haematological and
biochemical analyses were conducted in the animals before
their inclusion in the study. Surgical sectioning of the anterior
cruciate ligament (ACL) of the right knee was performed on all
dogs, as previously described [13] but with modifications. This
model was created by sectioning of the ACL after joint capsule
opening under general anaesthesia with pentobarbital sodium
(25 mg/kg). All dogs received a multimodal and pre-emptive
analgesic protocol based on opioid (fentanyl patch 75 μg
[Janssen-Ortho, Markham, ON, Canada] and meperidine 4
mg/kg subcutaneous injection [Sandoz, Montreal, QC, Can-
ada]) and intra-articular analgesia (marcaine 1 mg/kg [Hos-
pira, Quebec, QC, Canada]). During the postoperative period,
if needed, dogs were treated with fentanyl patch, oxymor-
phone (0.1 mg/kg SC; Sandoz) or meperidine SC, repeated
as necessary. After surgery, the dogs were housed on a farm
where they were free to exercise in a large enclosure. All dogs
actively exercised in exterior runs (1.35 m [width] × 9.15 m
[length]) for a 2-hour period, 5 days a week, under the super-
vision of an animal care technician.
The OA dogs were randomly assigned to two treatment
groups, to which the animal care personnel were blinded.
Dogs assigned to group 1 (n = 8) received placebo treatment
(encapsulated methylcellulose) and those assigned to group 2
(n = 8) received ASU (Piascledine™; Expanscience, Courbev-
oie, France) orally once a day, every day including weekends,
at a dosage of 10 mg/kg per day, which corresponds to twice
the recommended daily dosage for the treatment of patients
with knee or hip OA. The dosage was established based on
the recent FDA guidelines [14]. Drug treatment was initiated
immediately after surgery and continued until the dogs were
euthanized 8 weeks later. The study protocol was approved by
the institutional ethics committee and conducted in accord-
ance with the Canadian Council on Animal Care guidelines.
Macroscopic grading
Immediately after sacrifice, the right knee of each dog was
placed on ice and dissected. Each knee was examined for
gross morphological changes, as previously described, by two
independent observers who were blinded to treatment group
allocation [13].
The degree of osteophyte formation was graded by measuring
the maximal width (mm) of the spurs on the medial and lateral
femoral condyles using a digital caliper (Digimatic Caliper;
Mitutoyo Corporation, Kawasaki, Japan). These two values,
recorded for each dog, were considered separately for the
purposes of statistical analysis.
The medial and lateral menisci of each knee were also scored
macroscopically at the time of dissection as intact, fibrillated or
torn, based on a method modified from that reported by Cook
and coworkers [15].
The macroscopic lesion sizes at the cartilage surface were
measured (in mm2) as previously described [13]. OverallAvailable online http://arthritis-research.com/content/11/2/R41
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scores were obtained for the femoral condyles and tibial pla-
teaus separately by summing the score for each region
recorded.
Histological grading
Full thickness cartilage sections were removed from the
weight-bearing lesional areas of the femoral condyles and tib-
ial plateaus, allowing standardization of sampling as recom-
mended by the OA Research Society International guidelines
[15]. Histological evaluation was performed on sagittal sec-
tions of cartilage removed from each femoral condyle and tibial
plateau specimen [16]. Specimens were dissected, fixed in
TissuFix #2 (Laboratoires Gilles Chaput, Montreal, QC, Can-
ada) and embedded in paraffin for histological evaluation.
Serial sections (5 μm) were stained with Safranin-O. Two
independent observers (CB and JC), who were blinded to
treatment group allocation, graded the severity (consensus
score) of the OA lesions in each cartilage section, which was
divided into three subregions [15], on a scale of 0 to 29, mod-
ified from that reported by Sakakibara and colleagues [17].
This scale was used to evaluate the severity of OA lesions
based on the loss of Safranin-O staining (scale 0 to 4), cellular
changes (scale 0 to 12), structural changes (scale 0 to 10,
where 0 = normal cartilage structure and 10 = complete dis-
organization) and pannus formation (scale 0 to 3). The final
score (range 0 to 87) corresponds to the sum of the final
scores for the three subregions of each specimen from the
femoral condyle or tibial plateau.
Synovial membrane was removed and processed as
described above for histological analysis. Samples were
stained with haematoxylin-phloxine-saffron. The severity of syn-
ovitis was graded on a scale of 0 to 10 [13] by two blinded
and independent observers (CB and JC, consensus score),
who added the scores of histologic criteria: synovial cell hyper-
plasia (scale 0 to 2), villous hyperplasia (scale 0 to 3), and
mononuclear (scale 0 to 4) and polymorphonuclear (scale 0 to
1) cell infiltration; 0 indicates normal structure.
Subchondral bone and calcified cartilage 
histomorphometry
Specimens of full-thickness sections, which included the cal-
cified cartilage and subchondral bone, were removed from the
OA knee of all dogs and were placed in 70% ethanol and fur-
ther decalcified with rapid bone decalcifier (RDO; Apex Engi-
neering, Aurora, IL, USA). Specimens were embedded in
paraffin for the purpose of histomorphometric analysis.
Sections (5 μm) of each specimen were subjected to hema-
toxylin/eosin staining. A Leitz Diaplan microscope (Leica
Microsystems, Wetzlar, Germany) connected to a personal
computer (Pentium IV based, using OSTEO II Image Analysis
Software [Bioquant, Nashville, TN, USA]) was used to con-
duct bone histomorphometry analysis.
Subchondral bone histomorphometry was performed on three
nonconsecutive sections of each specimen using our previ-
ously published method [18], modified from that of Matsui and
coworkers [19]. The calcified cartilage/subchondral bone
junction was used as the upper limit of each field. The depth
was measured from the upper limit to 2,000 μm. Measurement
of the bone surface (% of tissue surface) and trabecular thick-
ness (μm) followed standard conventions, as previously
described [18]. The measurement of the fields was then aver-
aged for each section. Values for each section were consid-
ered separately for the purposes of statistical analysis.
Calcified cartilage histomorphometry was also done on three
nonconsecutive sections of each specimen, as previously
described [18]. From each section, three representative fields
of 1,000 μm length (original magnification ×60) were
selected. The tidemark/cartilage and calcified cartilage/bone
junctions were used as upper and lower limits. The mean thick-
ness (mm) of the calcified cartilage was calculated. The meas-
urement made in the three fields was then averaged for each
section and the value of each section was considered
separately.
Immunohistomorphometry
Cartilage specimens from the condyles and plateaus were
processed for immunohistochemical analysis, as previously
described [16,20], fixed in TissuFix #2 (Laboratoires Gilles
Chaput) for 24 hours, and then embedded in paraffin. Serial
sections (5 μm) of paraffin-embedded specimens were placed
on Superfrost Plus slides (Fisher Scientific, Nepean, ON, Can-
ada), de-paraffinized in toluene, rehydrated in a reverse graded
series of ethanol and pre-incubated with 0.25 units/ml chon-
droitinase ABC (Sigma-Aldrich Canada, Oakville, ON, Can-
ada) in phosphate-buffered saline (PBS; pH 8.0) for 60
minutes at 37°C. The specimens were subsequently washed
in PBS, incubated in 0.3% Triton X-100 for 20 minutes, and
then placed in 3% hydrogen peroxide/PBS for 15 minutes.
Slides were further incubated with a blocking serum
(Vectastain ABC kit; Vector Laboratories, Inc., Burlingame,
CA, USA) for 60 minutes, after which they were blotted and
then overlaid with the primary antibody against the following:
inducible nitric oxide synthase (iNOS; 1/200, rabbit polyclo-
nal; Santa Cruz Biotechnology Inc. [ref. #SC-650], Santa
Cruz, CA, USA), matrix metalloproteinase (MMP)-1 (1/40 dilu-
tion, mouse monoclonal; Calbiochem ref. #444209; EMD Bio-
sciences, Darmstadt, Germany), MMP-13 (1/6, goat
polyclonal antibody; R&D Systems, Minneapolis, MN, USA), a
disintegrin and metalloproteinase domain with thrombospon-
din motifs (ADAMTS)5 (1/50, rabbit polyclonal; Cedarlane
[ref. #CL1-ADAMTS5], Hornby, ON, Canada) and ADAMTS4
(1/40, rabbit polyclonal; Cedarlane [ref. #CL1-ADAMTS4])
for 18 hours at 4°C in a humidified chamber.
Each slide was washed three times in PBS (pH 7.4), stained
using the avidin-biotin complex method (Vectastain ABC kit),Arthritis Research & Therapy    Vol 11 No 2    Boileau et al.
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and incubated in the presence of the biotin-conjugated sec-
ondary antibody for 45 minutes at room temperature followed
by the addition of the avidin-biotin-peroxidase complex for 45
minutes. All incubations were carried out in a humidified cham-
ber at room temperature and the colour was developed with
3,3'-diaminobenzidine (DAKO Diagnostics Canada Inc., Mis-
sissauga, ON, Canada) containing hydrogen peroxide. The
slides were counterstained with haematoxylin/eosin.
To determine the specificity of staining, three control proce-
dures were employed in accordance with the same experimen-
tal protocol: omission of the primary antibody; substitution of
the primary antibody with an autologous preimmune serum;
and immunoadsorption with immunizing peptide for iNOS
(Santa Cruz Biotechnology Inc.) and ADAMTS4 and
ADAMTS5 (Cedarlane) or MMP-1 and MMP-13 recombinant
protein (R&D Systems). As previously demonstrated, all con-
trols exhibited only background staining (data not shown) [16].
Each section was examined under a light microscope (Leitz
Orthoplan; Leica Inc., St. Laurent, QC, Canada) and photo-
graphed using a CoolSNAP cf Photometrics camera (Roper
Scientific, Rochester, NY, USA).
The presence of the antigen in the cartilage was quantified
using our previously reported method [13,16,21]. and esti-
mated by determining the number of chondrocytes that
stained positive throughout the entire thickness of the carti-
lage. Three sections from each femoral condyle and tibial pla-
teau were examined, and each one was separately scored. The
resulting data were integrated as a mean for each specimen.
The cartilage was divided into six microscopic fields – three in
the superficial zone and three in the deep zone (×40; Leica
Inc.) – and the results were averaged for each zone. Before
evaluation, it was ensured that an intact cartilage surface for
each OA specimen could be detected and used as a marker
for validation of the morphometric analysis. The superficial
zone of cartilage corresponds to the superficial and the upper
intermediate layers, and the deep zone to the lower intermedi-
ate and deep layers. The total number of chondrocytes and
those staining positive in each zone for the specific antigen
were determined. The final results were expressed as the per-
centage of chondrocytes staining positive for the antigen (cell
score), with the maximum score being 100%. Each slide was
subjected to two independent readers who were blinded to
treatment group allocation. The final score was a consensus
between the two observers (CB and JC).
For the purposes of statistical analysis, the data obtained from
the femoral condyles and tibial plateaus were considered sep-
arately. iNOS, MMP-1, ADAMTS4 and ADAMTS5 were quan-
tified in the superficial zone of cartilage because the staining
for these antigens was found to be negligible in the deep zone,
whereas MMP-13 was quantified in the deep zone, which is its
preferential zone of expression [22].
Statistical analysis
Macroscopic and histologic data are expressed as mean ±
standard error of the mean. Immunohistochemical and histo-
morphometric results are expressed as the median (range).
Statistical analysis, unless otherwise specified, was performed
using the Mann-Whitney U-test or Student's unpaired t-test. P
values of less than or equal to 0.05 were considered statisti-
cally significant.
Results
Macroscopic findings
Osteophytes
The incidence and size of the osteophytes were similar for
both groups, with a mean size of 4.77 ± 0.32 mm (mean ±
standard error of the mean) for the placebo group and 5.24 ±
0.30 mm for the ASU-treated group.
Meniscus
The macroscopic evaluation of the medial and lateral menisci
revealed no difference between placebo and ASU-treated
groups. In the medial compartment, two of the eight dogs in
the placebo group exhibited a meniscal tear, as compared with
three in the ASU-treated group; five of the eight dogs in the
placebo group had a fibrillated meniscus versus four in the
ASU-treated group; and one dog in each group had an intact
medial meniscus. In the lateral compartment, six of the eight
dogs in the placebo group had an intact lateral meniscus ver-
sus seven in the ASU-treated group, and two menisci were
fibrillated in the placebo group versus one in the ASU-treated
group.
Cartilage
The severity (surface) of the lesions on the tibial plateaus was
significantly decreased in the ASU-treated dogs (50.5 ± 4.0
mm2) compared with the placebo-treated group (67.1 ± 6.1
mm2; P = 0.04; Figure 1). The severity (surface) of the lesions
on the femoral condyles in the ASU-treated dogs (29.3 ± 5.7
mm2) was less than that in the placebo-treated dogs (38.1 ±
5.5 mm2; Figure 1).
Histological findings
Cartilage
The cartilage specimens from the dogs treated with placebo
exhibited modifications that are typical of OA. The total histo-
logical scores for the severity of cartilage lesions on the femo-
ral condyles and the tibial plateaus were significantly
decreased in the ASU-treated dogs compared with those
treated with placebo (P < 0.0001 for femoral condyles and P
= 0.0002 for tibial plateaus; Figure 2 and Table 1). On the
femoral condyles and tibial plateaus, the scores of all parame-
ters were significantly decreased in the ASU-treated group
compared with the placebo-treated group, with the exception
of the Safranin-O staining and the pannus on the plateaus
(Table 1).Available online http://arthritis-research.com/content/11/2/R41
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Synovial membrane
The synovial membranes from the placebo-treated dogs exhib-
ited hyperplasia of the lining cells, villous hyperplasia and
mononuclear cellular infiltration. ASU treatment induced a
slight reduction in the total histological score (7.13 ± 0.48 for
the placebo group and 5.63 ± 0.56 for the ASU-treated
group). The histological score was identical in both groups for
all of the criteria except for cellular infiltration. Indeed, ASU
induced a significant decrease in cellular infiltration (3.00 ±
0.19 for the placebo group and 1.50 ± 0.50 [P = 0.04] for the
ASU-treated group).
Bone histomorphometric analysis
Bone surface was 75.9% (50.8% to 86.2%; median [range])
of the tissue surface in the placebo group compared with
79.3% (66.0% to 90.8%; P < 0.05) in the ASU-treated group
(Figure 3). Trabecular thickness did not differ between the
ASU (132.3 μm [102.8 μm to 200.5 μm]) and placebo (129.1
μm [90.0 μm to 156.0 μm]) groups.
The calcified cartilage thickness was significantly greater in
the ASU group (102.9 μm [85.5 μm to 138.7 μm]) than in the
placebo group (91.2 μm [55.2 μm to 145.9 μm]; P = 0.01).
Immunohistomorphometric findings
Chondrocytes staining positive for iNOS were found preferen-
tially located in the superficial zone of the OA cartilage. The
percentage of positive cells was found to be significantly
decreased in the ASU-treated group (21.4% [19.3% to
27.6%]) compared with the placebo-treated group (25.6%
[21.2% to 30.1%]; P = 0.02; Figure 4).
In contrast to iNOS, MMP-13 was detected preferentially in
the deep zone of OA cartilage. Dogs treated with ASU exhib-
ited a significant reduction in the level of MMP-13 (8.6%
[4.8% to 13.10%]) compared with the placebo-treated group
(16.3% [9.0% to 24.8%]; P = 0.01; Figure 5).
The levels of other mediators were also studied and found to
be similar in the two groups: MMP-1, 28.0% (23.2% to
30.9%) of chondrocytes in the placebo group versus 29.6%
(27.8% to 30.7%) in the ASU-treated group; ADAMTS4,
23.9% (22.0% to 28.2%) versus 26.9% (22.9% to 28.9%);
and ADAMTS5, 24.6% (20.7% to 29.8%) versus 26.05%
(17.9% to 29.5%).
Discussion
In the experimental dog OA model induced by the sectioning
of the ACL, treatment with ASU can reduce the development
of early OA cartilage and subchondral bone lesions. The histo-
logical findings were informative with respect to the effects of
ASU on the OA cartilage structural changes. In fact, dogs
treated with ASU exhibited a significant decrease in indicators
of cartilage matrix damage, such as the structural changes
indicative of collagen network breakdown and Safranin-O
staining, which indicates aggrecan degradation. In addition,
treatment with ASU was found to reduce chondrocyte hyper-
plasia and cloning. These findings are in accordance with
those of Cake and coworkers [9] in an ovine meniscectomy
model of OA.
Many proteases have been shown to play major roles in the
catabolism of OA cartilage. For instance, MMP-13 has been
demonstrated to play a predominant role in the degradation of
collagen type II in OA cartilage [23], whereas ADAMTS4 and
ADAMTS5 are believed to be key proteases in the degradation
Figure 1
Macroscopic appearance of osteoarthritic articular cartilage from femo- ral condyles and tibial plateaus Macroscopic appearance of osteoarthritic articular cartilage from femo-
ral condyles and tibial plateaus. Representative pictures of placebo-
treated and ASU-treated dogs at 8 weeks after surgery, showing ero-
sion and pitting (circled). A, anterior; L, lateral; M, medial; P, posterior.
Figure 2
Histology of osteoarthritic articular cartilage from the femoral condyles  and tibial plateaus Histology of osteoarthritic articular cartilage from the femoral condyles 
and tibial plateaus. Representative sections of placebo-treated and 
ASU-treated dogs 8 weeks post-surgery (original magnification ×100). 
Sections were stained with Safranin-O. ASU, avocado/soybean 
unsaponifiables.Arthritis Research & Therapy    Vol 11 No 2    Boileau et al.
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of aggrecans [24,25]. In the ACL dog model, inhibition of the
synthesis of these enzymes by treatment with different drugs,
such as pioglitazone (a peroxisome proliferator-activated
receptor-γ agonist [26]) and licofelone (a dual inhibitor of 5-
lipoxygenase and cyclo-oxygenase [27]), has been found to be
associated with a reduction in the development of cartilage
lesions. These enzymes, by cleaving the triple helix of collagen
type II and core protein of the aggrecan respectively, induce
major irreversible damage to the cartilage matrix structure. In
so doing, they can modify the biophysical properties of carti-
lage and reduce its resilience to the abnormal biomechanical
forces present in OA.
In the present study, treatment with ASU reduced the level of
MMP-13 synthesis in the deep zone of cartilage. These find-
ings are in accordance with a previous study in which ASU
were demonstrated to reduce MMP-13 mRNA in murine
chondrocytes in monolayer culture under stimulation with IL-
1β [28]. MMP-13 expression is increased in tissue that is in
need of repair or remodelling, as in OA. MMP-13 was previ-
ously shown to be preferentially increased in the deep zone of
cartilage [22,29]. and was described as a major catabolic fac-
tor in that zone as well as in OA lesional areas [30,31]. There-
fore, our finding of the effect of ASU treatment on reduction in
MMP-13 synthesis could explain the prevention of OA carti-
lage lesion development as well as the protective effect of
ASU on the erosion of the calcified cartilage [19]. On the other
hand, ASU were found to have no effect on the level of synthe-
sis of other proteases involved in cartilage matrix degradation,
such as MMP-1, ADAMTS4 and ADAMTS5; these enzymes
are believed to be predominantly involved in matrix degrada-
tion in the more superficial zones of cartilage. These results
support the hypothesis that the reduction in collagen degrada-
tion in the deep zone of cartilage could reduce the develop-
ment of OA lesions. Alternatively, the absence of effect on the
above proteases may explain the mild to moderate effect that
ASU had on the reduction in OA cartilage lesions.
MMP-13 is known to be involved in subchondral bone remod-
elling and resorption of calcified cartilage in OA [18]. As pre-
viously demonstrated by Cake and coworkers [9], ASU
treatment was able to protect the remodelling of subchondral
bone in an ovine OA model. Moreover, studies suggest that
drugs that can reduce MMP-13 synthesis in cartilage and
bone and prevent subchondral bone resorption in the dog
ACL model could exert a disease-modifying effect in knee OA
patients [18,27]. Our findings demonstrate that ASU could
reduce OA subchondral bone remodelling and resorption,
which leads to osteopenia, a phenomenon well documented in
Table 1
Histological score of femoral condyles and tibial plateaus of placebo and ASU-treated dogs
Treatment 
group
Structure 
(0 to 30)a
Tangential 
(0 to 6)a
Transitional 
(0 to 30)a
Safranin-O 
staining 
(0 to 12)a
Pannus 
(0 to 9)a
Total (0 to 87)a
Femoral 
condyles
Placebo 20.50 ± 0.92 5.75 ± 0.19 15.63 ± 0.70 4.69 ± 0.33 0.88 ± 0.24 47.55 ± 1.74
ASU 
(10 mg/kg)
11.44 ± 0.90 
(P < 0.0001)
3.81 ± 0.25 
(P < 0.0001)
12.88 ± 0.42 
(P = 0.006)
3.69 ± 0.24 
(P = 0.03)
0.19 ± 0.10 
(P = 0.004)
32.31 ± 1.64 
(P < 0.0001)
Tibial plateaus Placebo 20.69 ± 0.64 5.75 ± 0.14 16.88 ± 0.79 4.75 ± 0.40 1.75 ± 0.34 49.81 ± 1.86
ASU 
(10 mg/kg)
13.25 ± 1.52 
(P < 0.0001)
4.19 ± 0.28 
(P = 0.0002)
13.06 ± 0.55 
(P = 0.001)
4.25 ± 0.31 1.62 ± 0.36 36.38 ± 2.07 
(P = 0.0002)
The score was determined as described in the Materials and methods section. The final score corresponds to the sum of the scores obtained for 
the three subregions. Data are expressed as mean ± standard error of the mean and were analyzed using Mann-Whitney two-tailed U-test. 
Comparison was performed with the autologous placebo and P = 0.05 is considered statistically significant. aThe values given in parentheses 
indicates the range for each measure. ASU, avocado/soybean unsaponifiables.
Figure 3
Subchondral bone and calcified cartilage Subchondral bone and calcified cartilage. Representative sections and 
data of placebo-treated and ASU-treated dogs 8 weeks post-surgery 
(original magnification ×100). Sections were stained with haematoxy-
lin/eosin. Data for bone volume and calcified cartilage thickness are 
represented as box plot and were analyzed using Student's unpaired t-
test. P ≤ 0.05 is considered significant. ASU, avocado/soybean 
unsaponifiables.Available online http://arthritis-research.com/content/11/2/R41
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the ACL dog OA model that occurs during the first few months
after surgery [32,33]. The bone volume and calcified cartilage
thickness in the ASU-treated group were greater than those
found in the placebo group and close to the morphometric val-
ues found in normal dogs [18]. These findings indicate that the
ASU treatment reduced the loss of subchondral bone. Moreo-
ver, ASU treatment was able to maintain subchondral bone
and calcified cartilage structure close to normal values.
ASU treatment prevented the loss, but it did not increase bone
surface or calcified cartilage thickness over the values found
in normal dogs [18]. These data also support the concept that
the subchondral bone is the site of morphological changes
that are part of the OA disease process [5,8,10-12,18,34],
and provide further evidence in favour of the concept that ther-
apeutic intervention to reduce these changes may also pre-
vent the development of cartilage lesions. This latter
hypothesis is further supported by a number of published stud-
ies showing that, in ACL OA models, treatment with calcitonin
[33] and alendronate [35] reduced bone resorption as well as
cartilage degeneration. In this context, the study conducted by
Henrotin and coworkers [36], in which ASU reversed the inhi-
bition of aggrecan and collagen synthesis in OA chondrocyte/
osteoblast co-culture, is supportive of the existence and key
role played by the crosstalk between cartilage and subchon-
dral bone in OA pathophysiology.
In contrast to normal cartilage, OA cartilage produces an
excess amount of nitric oxide (NO) upon iNOS (the enzyme
responsible for NO production) stimulation by cytokines
[37,38]. High levels of nitrite/nitrate have also been found in
the synovial fluid and serum of arthritis patients [39] as well as
in synovial tissue from OA patients [40,41]. It has been
hypothesized that NO contributes to the development of
arthritic lesions [42-44] by inhibiting the synthesis of cartilage
matrix macromolecules [45-48] and by inducing chondrocyte
death [49,50], which could further contribute to the reduction
in extracellular matrix in OA. NO was also shown to reduce the
synthesis of the IL-1 receptor antagonist in chondrocytes [38],
a process possibly responsible for the enhanced IL-1β effect
on these cells. Moreover, the diffusion of NO from the superfi-
cial layer of cartilage to the deeper zone may also have contrib-
uted to increasing the level of MMP-13 synthesis at that level
[51]. An in vivo study with N-iminoethyl-L-lysine, a potent and
selective iNOS inhibitor [52], demonstrated its therapeutic
effectiveness in reducing the progression of experimental OA
in the ACL dog model [53]. The same study also demon-
strated that iNOS inhibition reduced the synovial inflammation,
a finding that is well in agreement with those of the present
study. Moreover, ASU exhibited an inhibitory effect on iNOS,
and therefore on NO production, which may provide an expla-
nation for the protective effect of ASU. These results are in
accordance with those of a study in human OA chondrocytes
previously published by Henrotin and coworkers [54].
The present study has limitations largely imposed by the study
design. One such limitation is the duration of the study (8
weeks). A longer study would provide more information on the
Figure 4
iNOS immunostaining iNOS immunostaining. Representative sections and data of the superfi-
cial zone of articular cartilage from placebo-treated and ASU-treated 
dogs (original magnification ×100). Morphometric analysis of iNOS 
immunostaining data are represented as box plot and were analyzed 
using Mann-Whitney two-tailed U-test. P ≤ 0.05 is considered statisti-
cally significant. ASU, avocado/soybean unsaponifiables; iNOS, induci-
ble nitric oxide synthase.
Figure 5
MMP-13 immunostaining MMP-13 immunostaining. Representative sections and data of the 
deep zone of articular cartilage from placebo-treated and ASU-treated 
dogs (original magnification ×250). Morphometric analysis of MMP-13 
immunostaining data are represented as box plot and were analyzed 
using Mann-Whitney two-tailed U-test. P ≤ 0.05 is considered statisti-
cally significant. ASU, avocado/soybean unsaponifiables; MMP, matrix 
metalloproteinase.Arthritis Research & Therapy    Vol 11 No 2    Boileau et al.
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potential effects of ASU against the long-term development of
OA. Moreover, the study design involved prophylactic use of
the drug and the conclusions drawn might have been influ-
enced by this treatment schedule. A further study in which
therapeutic administration is employed would be informative
and complementary to the present one. The mechanisms of
action of ASU, especially their global effect on catabolic/ana-
bolic factors, needs further investigation in order to reach a
better understanding of the disease pathways that are modi-
fied by this treatment.
Conclusions
The present findings indicate that the protective effect of ASU
on OA structural changes could be mediated by a reduction in
cartilage catabolism and in subchondral bone remodelling,
which may be due, at least in part, to their inhibitory effects on
iNOS and MMP-13.
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